| Literature DB >> 24465432 |
Laura Farnan1, Anastasia Ivanova2, Shyamal D Peddada3.
Abstract
Constraints arise naturally in many scientific experiments/studies such as in, epidemiology, biology, toxicology, etc. and often researchers ignore such information when analyzing their data and use standard methods such as the analysis of variance (ANOVA). Such methods may not only result in a loss of power and efficiency in costs of experimentation but also may result poor interpretation of the data. In this paper we discuss constrained statistical inference in the context of linear mixed effects models that arise naturally in many applications, such as in repeated measurements designs, familial studies and others. We introduce a novel methodology that is broadly applicable for a variety of constraints on the parameters. Since in many applications sample sizes are small and/or the data are not necessarily normally distributed and furthermore error variances need not be homoscedastic (i.e. heterogeneity in the data) we use an empirical best linear unbiased predictor (EBLUP) type residual based bootstrap methodology for deriving critical values of the proposed test. Our simulation studies suggest that the proposed procedure maintains the desired nominal Type I error while competing well with other tests in terms of power. We illustrate the proposed methodology by re-analyzing a clinical trial data on blood mercury level. The methodology introduced in this paper can be easily extended to other settings such as nonlinear and generalized regression models.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24465432 PMCID: PMC3897384 DOI: 10.1371/journal.pone.0084778
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Results of a simulation study to compare power and sample sizes of F-test in One-way ANOVA with the constrained inference Williams’ type test where the critical values are derived using 10,000 bootstrap samples.
The power of the Williams test was estimated by averaging 1000 simulated where the critical values are estimated using 10,000 bootstrap samples. The power for F-test was determined using PROC POWER in SAS (9.0). The null hypothesis was that the means of the four dose groups were equal (and zero) and the alternative hypothesis was that the means of the four dose groups have an increasing trend with dose. Data representing the four dose groups were simulated from normal populations with dose means taken to be 0, 0.1, 0.5 and 1, respectively. The actual values of the doses are irrelevant for the two methods described here. The population standard deviation for the four populations was taken to be 1. Corresponding to the 14 different patterns of total sample sizes, namely, 20, 24, 28, 32, 36, 40, 44, 48, 52, 60, 76, 80, 100, 116, the powers of the two methods are plotted. The Type I error was set to 0.05.
Figure 2Flow chart for constructing test statistic.
Figure 3Flow chart for deriving Bootstrap data under the null hypothesis.
Type I errors for homoscedastic normally distributed data.
|
|
|
| Asymp-LRT | Proposed method |
| 3 | 10 | 1 | 0.03 | 0.05 |
| 3 | 50 | 1 | 0.01 | 0.03 |
| 3 | 10 | 0.2 | 0.05 | 0.04 |
| 3 | 10 | 2 | 0.04 | 0.05 |
| 3 | 50 | 2 | 0.01 | 0.03 |
| 5 | 10 | 1 | 0.02 | 0.03 |
| 5 | 10 | 0.2 | 0.02 | 0.04 |
| 5 | 10 | 2 | 0.02 | 0.04 |
Power for homoscedastic normally distributed data.
|
|
|
|
| Asymp-LRT | Proposed method | |||||||||
| 3 | 10 | 0 | 0.00 | 1.25 | 1 | 0.82 | 0.84 | |||||||
| 3 | 10 | 0 | 1.26 | 1.26 | 1 | 0.82 | 0.84 | |||||||
| 3 | 50 | 0 | 0.55 | 0.55 | 1 | 0.85 | 0.89 | |||||||
| 3 | 10 | 0 | 0.73 | 1.45 | 1 | 0.86 | 0.89 | |||||||
| 5 | 10 | 0 | 0.00 | 0.00 | 0.00 | 1.27 | 1 | 0.65 | 0.86 | |||||
| 5 | 10 | 0 | 1.24 | 1.24 | 1.24 | 1.24 | 1 | 0.58 | 0.86 | |||||
| 5 | 10 | 0 | 0.37 | 0.74 | 1.11 | 1.48 | 1 | 0.80 | 0.90 | |||||
| 5 | 10 | 0 | 0.81 | 0.81 | 0.81 | 1.62 | 1 | 0.74 | 0.93 | |||||
Type I errors for heteroscedastic normally distributed data.
|
|
|
|
| Asymp-LRT | Proposed method | ||||
| 3 | 10 | 0.1 | 0.10 | 2.37 | 1 | 0.04 | 0.03 | ||
| 3 | 10 | 0.1 | 0.20 | 0.20 | 1 | 0.03 | 0.04 | ||
| 3 | 10 | 0.1 | 0.09 | 0.36 | 1 | 0.03 | 0.03 | ||
| 3 | 50 | 0.1 | 0.10 | 0.01 | 1 | 0.01 | 0.03 | ||
| 3 | 50 | 0.1 | 0.02 | 0.02 | 1 | 0.02 | 0.04 | ||
| 5 | 10 | 0.1 | 0.10 | 0.10 | 0.10 | 0.16 | 1 | 0.01 | 0.04 |
| 5 | 10 | 0.1 | 0.20 | 0.20 | 0.20 | 0.20 | 1 | 0.01 | 0.04 |
| 5 | 10 | 0.1 | 0.11 | 0.44 | 0.99 | 1.76 | 1 | 0.01 | 0.04 |
| 5 | 10 | 0.1 | 0.11 | 0.11 | 0.11 | 0.45 | 1 | 0.02 | 0.05 |
Power for heteroscedastic normally distributed data.
|
|
|
|
| Asymp-LRT | Proposed method | ||||
| 3 | 10 | 0 | 0.00 | 1.54 | 1 | 0.82 | 0.88 | ||
| 3 | 10 | 0 | 0.45 | 0.45 | 1 | 0.81 | 0.82 | ||
| 3 | 10 | 0 | 0.30 | 0.60 | 1 | 0.82 | 0.80 | ||
| 3 | 50 | 0 | 0.00 | 0.10 | 1 | 0.70 | 0.74 | ||
| 3 | 50 | 0 | 0.15 | 0.15 | 1 | 0.86 | 0.92 | ||
| 3 | 50 | 0 | 0.08 | 0.16 | 1 | 0.95 | 0.93 | ||
| 5 | 10 | 0 | 0.00 | 0.00 | 0.00 | 0.40 | 1 | 0.42 | 0.78 |
| 5 | 10 | 0 | 0.45 | 0.45 | 0.45 | 0.45 | 1 | 0.68 | 0.81 |
| 5 | 10 | 0 | 0.33 | 0.66 | 1.00 | 1.33 | 1 | 0.96 | 0.88 |
| 5 | 10 | 0 | 0.34 | 0.34 | 0.34 | 0.67 | 1 | 0.71 | 0.82 |
Type I errors for log-normally distributed data.
|
|
|
|
| Asymp-LRT | Proposed method | ||||
| 3 | 10 | 0.10 | 0.10 | 0.04 | 1 | 0.02 | 0.03 | ||
| 3 | 10 | 0.10 | 0.20 | 0.20 | 1 | 0.03 | 0.05 | ||
| 3 | 10 | 0.10 | 0.01 | 0.04 | 1 | 0.03 | 0.03 | ||
| 3 | 50 | 0.10 | 0.02 | 0.02 | 1 | 0.01 | 0.01 | ||
| 3 | 50 | 0.10 | 0.01 | 0.03 | 1 | 0.01 | 0.01 | ||
| 5 | 10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.16 | 1 | 0.02 | 0.04 |
| 5 | 10 | 0.10 | 0.04 | 0.04 | 0.04 | 0.04 | 1 | 0.02 | 0.03 |
| 5 | 10 | 0.10 | 0.01 | 0.04 | 0.09 | 0.16 | 1 | 0.02 | 0.05 |
| 5 | 10 | 0.10 | 0.01 | 0.01 | 0.01 | 0.04 | 1 | 0.03 | 0.03 |
Power for log-normally distributed data.
|
|
|
|
| Asymp-LRT | Proposed method | ||||
| 3 | 10 | 0 | 0.00 | 1.54 | 1 | 0.90 | 0.98 | ||
| 3 | 10 | 0 | 0.45 | 0.45 | 1 | 0.81 | 0.85 | ||
| 3 | 10 | 0 | 0.30 | 0.60 | 1 | 0.85 | 0.90 | ||
| 3 | 50 | 0 | 0.00 | 0.20 | 1 | 0.92 | 0.88 | ||
| 3 | 50 | 0 | 0.15 | 0.15 | 1 | 0.57 | 0.68 | ||
| 3 | 50 | 0 | 0.08 | 0.16 | 1 | 0.89 | 0.69 | ||
| 5 | 10 | 0 | 0.00 | 0.00 | 0.00 | 0.40 | 1 | 0.44 | 0.77 |
| 5 | 10 | 0 | 0.45 | 0.45 | 0.45 | 0.45 | 1 | 0.66 | 0.83 |
| 5 | 10 | 0 | 0.10 | 0.20 | 0.30 | 0.40 | 1 | 0.79 | 0.75 |
| 5 | 10 | 0 | 0.34 | 0.34 | 0.34 | 0.67 | 1 | 0.72 | 0.94 |
| 5 | 50 | 0 | 0.00 | 0.00 | 0.00 | 0.20 | 1 | 0.97 | 0.96 |
| 5 | 50 | 0 | 0.20 | 0.20 | 0.20 | 0.20 | 1 | 0.66 | 0.92 |
| 5 | 50 | 0 | 0.08 | 0.08 | 0.08 | 0.16 | 1 | 0.87 | 0.74 |
Figure 4Normal quantile-quantile plots of studentized residuals from regressing log organic mercury in the placebo and succimer groups.